{
    "Trade/Device Name(s)": [
        "ReliOn Premier BLU Blood Glucose Monitoring System"
    ],
    "Submitter Information": "i-SENS, Inc.",
    "510(k) Number": "K230625",
    "Predicate Device Reference 510(k) Number(s)": [
        "K170614"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "July 12, 2023",
    "Summary Letter Received Date": "July 14, 2023",
    "Submission Date": "July 28, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ReliOn Premier BLU Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection",
        "Bluetooth Low Energy communication"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for ReliOn Premier BLU Blood Glucose Monitoring System for self-testing blood glucose using a Bluetooth-enabled meter and test strips",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from fingertips by people with diabetes at home for self-testing to monitor effectiveness of diabetes control; not for neonates or diagnosis/screening of diabetes",
    "fda_folder": "Clinical Chemistry"
}